AOD-9604 5mg: The Fat-Burning Peptide Guide

AOD-9604

Growth hormone drives fat loss, but it also brings along a long list of other effects researchers don’t always want. Scientists set out to isolate just the fat-burning piece, and that effort produced AOD-9604, a modified fragment of the growth hormone molecule.

Isolating One Piece of a Larger Hormone

Australian researchers developed this peptide by identifying the specific region of human growth hormone responsible for fat metabolism, then synthesizing just that fragment on its own. The full growth hormone molecule influences muscle growth, blood sugar, and organ growth alongside fat metabolism, but this isolated piece appears to retain the fat-burning activity without triggering those other effects. That selective approach drove much of the early interest surrounding it.

How It Targets Fat Metabolism

This peptide appears to stimulate lipolysis, the breakdown of stored fat into usable energy, while also inhibiting lipogenesis, the process that creates new fat stores. Researchers believe it works through pathways similar to growth hormone’s fat-metabolizing effects, but without significantly affecting blood sugar regulation or tissue growth the way full growth hormone does. This targeted mechanism explains why it drew attention as a potential alternative to broader growth hormone therapies.

What a 5mg Vial Offers

Suppliers typically package this peptide as a freeze-dried powder, with 5mg representing a standard quantity for ongoing research protocols. Researchers reconstitute the powder with bacteriostatic water, then administer it via subcutaneous injection, often on an empty stomach to avoid interference from insulin release after eating. Because research protocols frequently call for daily dosing, the 5mg vial typically supports several weeks of a study without needing frequent replacement.

Where the Research Trail Goes Cold

Early research, including a notable Australian trial, initially suggested promising fat-loss results. However, subsequent clinical trials failed to replicate those early findings at the scale researchers hoped for, and the company developing it ultimately discontinued further clinical development. Despite that setback, interest persisted in research and fitness communities, keeping the compound in circulation well beyond its original clinical trial phase.

Safety and Regulatory Standing

No regulatory agency, including the FDA, has approved this peptide for human use or weight loss specifically. The FDA has explicitly flagged it as a compound not approved for compounding or human use. Sellers market it strictly as a research compound.

---

FAQ

What’s included in a 5mg AOD-9604 vial?
A freeze-dried powder requiring reconstitution with bacteriostatic water before administering via subcutaneous injection.

How is this peptide different from full growth hormone?
It isolates just the fat-metabolizing fragment of growth hormone, aiming to avoid effects on blood sugar and tissue growth.

Did clinical trials support its fat-loss claims?
Early trials showed promise, but later studies failed to replicate those results at scale, leading to discontinued clinical development.

When do research protocols typically administer it?
Often on an empty stomach, to avoid interference from insulin release that occurs after eating.

Is it approved for weight loss treatment?
No. The FDA hasn’t approved it, and it’s sold only as an unapproved research compound.